Hepatitis C


University of Michigan–Peking University Joint Initiative: Predictors of hepatitis C progression

Additional funding from the Bristol-Myers Squibb Foundation

Enrollment status: Actively enrolling

Objective

To identify genetic markers that predict the progression from chronic HCV infection to cirrhosis and HCC, along with identifying and validating blood markers of liver fibrosis and early HCC.

Inclusion/exclusion criteria

  • Adults with chronic hepatitis C, not currently taking antiviral medicine and no HIV coinfection.

Principal Investigator: Anna Lok, MD aslok@med.umich.edu

Contact Persons:
Sherry Fu (734) 647-3635 or sherryfu@med.umich.edu
Elizabeth Wu (734) 647-0236 or elizwu@med.umich.edu


Long-term follow up of patients who received asunaprevir (BMS-650032) and/or daclatasvir (BMS-790052) in previous clinical trials

Enrollment status: Actively enrolling

Objective

To determine the durability of virologic response in patients treated with asunaprevir and/or daclatasvir, assess the presence of HCV sequence variants, and characterize the long-term progression of liver disease.

Principal Investigator: Anna Lok, MD aslok@med.umich.edu

Contact person: Elizabeth Wu (734) 647-0236 or elizwu@med.umich.edu


Hepatitis C therapeutic registry and research network (HCV-TARGET) – a longitudinal, observational study

Enrollment status: Actively enrolling

Objective

To collect and study information on patients with chronic hepatitis C virus who are being treated with direct-acting antiviral agents in a “real world” patient population to determine:

  • Effectiveness of these drugs in differing patient populations

  • Compare treatment durations in differing groups of patients

  • How best to manage side effects

  • Genetic variances in drug response

  • Drug-to-drug interactions

  • Patient education – group versus individual

  • Pharmacy usage

  • Drug resistance

Principal Investigator: Anna Lok, MD aslok@med.umich.edu

Contact person: Elizabeth Wu (734) 647-0236 or elizwu@med.umich.edu